opens in new tab

Phosphoinositide 3-kinase in health and disease

0 ratings
2010
Berlin, Springer
Media group: Serien
Volumes

Content

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here.

Ratings

0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Details

Search for this author
Statement of Responsibility: Christian Rommel ; Bart Vanhaesebroeck ; Peter K. Vogt, editors
Year: 2010
Publisher: Berlin, Springer
opens in new tab
Classification: Search for this systematic ZB-90, MB-40
Subject type: Search for this subject type Sammelwerk
Description: Vols. 1 - 2
Tags: Immunbiologie; Medizinische Mikrobiologie
Participating parties: Search for this character Rommel, Christian [Hrsg.]; Vanhaesebroeck, Bart [Hrsg.]; Vogt, Peter K. [Hrsg.]
Language: englisch||
Footnote: Literaturangaben
Media group: Serien